Abstract | INTRODUCTION: METHODS: Between June 2008 and August 2011, a total of 50 patients with relapsed or refractory SCLC were treated with belotecan 0.5 mg/m for 5 consecutive days, every 3 weeks. We evaluated the overall response rate (ORR), the progression-free survival (PFS), and the overall survival (OS), and toxicity according to sensitivity to initial chemotherapy. RESULTS: The median age was 66 years (range, 43-84 years) and Eastern Cooperative Oncology Group performance was 0 or 1 in 34 patients (68%) and 2 in 16 patients (32%). Twenty patients (40%) had sensitive relapse and 30 patients (60%) had refractory disease. The ORR, PFS, and OS for sensitive patients were 20% (95% confidence interval [CI], 8-40), 2.8 months (95% CI, 0.53-5.06), and 6.5 months (95% CI, 1.58-11.42), respectively. In the refractory group, the ORR, PFS, and OS were 10% (95% CI, 1-21), 1.5 months (95% CI, 1.25-1.75), and 4.0 months (95% CI, 3.40-4.60), respectively. Most commonly reported grade-3 or -4 adverse events included neutropenia (54%), thrombocytopenia (38%), and anemia (32%). CONCLUSION:
Belotecan showed modest activity with an acceptable safety profile as a second-line therapy in patients with relapsed or refractory SCLC.
|
Authors | Gun Min Kim, Young Sam Kim, Young Ae Kang, Jae-Heon Jeong, Sun Mi Kim, Yun Kyoung Hong, Ji Hee Sung, Seung Taek Lim, Joo Hang Kim, Se Kyu Kim, Byoung Chul Cho |
Journal | Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer
(J Thorac Oncol)
Vol. 7
Issue 4
Pg. 731-6
(Apr 2012)
ISSN: 1556-1380 [Electronic] United States |
PMID | 22425922
(Publication Type: Journal Article, Research Support, Non-U.S. Gov't)
|
Chemical References |
- Topoisomerase I Inhibitors
- belotecan
- Camptothecin
|
Topics |
- Adult
- Aged
- Aged, 80 and over
- Camptothecin
(adverse effects, analogs & derivatives, therapeutic use)
- Carcinoma, Small Cell
(drug therapy, mortality)
- Disease-Free Survival
- Female
- Humans
- Lung Neoplasms
(drug therapy, mortality)
- Male
- Middle Aged
- Neoplasm Recurrence, Local
(drug therapy)
- Retrospective Studies
- Topoisomerase I Inhibitors
(therapeutic use)
|